Loading
Rezolute, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 31 Mar 2026.
Rezolute, Inc.: what insiders have been doing
Every trade that managers of Rezolute, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. Between 18 October 2025 and 18 October 2026, 10 insiders published 23 filings.
Not one open-market sale was filed. On the buying side, 5 insiders reported 6 purchases totalling €194k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. At €60k, the purchase published on 15 December 2025 by Evans Daron is the largest of the period. On the buying side, the filings list 3 senior executives, 1 finance chief and 1 chief executive among the declarants.
The data flag 5 purchases as part of a group of insiders buying within 30 days of each other. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The last insider purchase was made public on 31 March 2026, 201 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade.
For context, the typical company on the same exchange (median of 5,458 companies) published 22 filings over the same period, against 23 filings here. The full history, which starts in 2016, counts 39 purchases against 1 sale. The 10-K for the year ended 30 June 2026 shows -77.6 m USD of net income.
Other companies in the same sector with recent insider buying flagged by our signals: Anixa Biosciences Inc and Vivos Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
75
Thresholds
n/a
Buy Volume
€9M
39 ops. · all time
Sell Volume
n/a
1 ops. · all time
Who traded when
BuySaleDaron Evans7 buys
Brian Kenneth Roberts2 buys
Nevan C. Elam2 buys
Wladimir Hogenhuis2 buys
Nerissa Kreher1 buy
Sunil Ratilal Karnawat1 buy
+1 other insider
Since the insiders bought
- +14.4%Entry US$3.13 · Close 16 Oct 2026 US$3.58
- +28.6%Entry US$1.85 · Close at T+90 US$2.38
- +28.6%Entry US$1.85 · Close at T+90 US$2.38
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Rezolute, Inc. Strong Buy (bullish), based on 10 analysts. Average price target: US$9.80.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended June 2025 · cache
US$3.58
Analyst consensus
10 analystsStrong buy
US$6.00Target US$9.80(+174%)US$15.00
Income statement
EBITDA-US$79.9M
Net income-US$74.4M0.0% margin
Valuation
PER (forward)-7.6x
P/Book3.4x
Beta0.54
Balance sheet & cash
Market capUS$346.3M
Total debtUS$1.6M
Free Cash Flow-US$69.1M
Debt / Equity1%
Profitability & ownership
ROE-59.0%
ROA-35.3%
% insiders9.7%
% institutions98.7%
Last declaration on 3 September 2026
Declarations75 total
2,267 shares@ US$4.500.0027% mcap34.7% of flowCommon SharesSEC:0000912282-26-001216:0
8,004 shares@ US$4.990.011% mcap18.5% of flowCommon SharesSEC:0000912282-26-000930:0
3,062 shares@ US$4.990.0040% mcap2.2% of flowCommon SharesSEC:0000912282-26-000929:0
3,062 shares@ US$4.990.0040% mcap5.7% of flowCommon SharesSEC:0000912282-26-000936:0
10,000 shares@ US$2.854.0% of flowCommon SharesSEC:0000912282-26-000533:0
Canonical exit: 28 Jun 2026 (T+90)
27,618 shares@ US$2.9937.2% of flowCommon SharesSEC:0000912282-26-000410:0
11,439 shares@ US$2.9912.4% of flowCommon SharesSEC:0000912282-26-000412:0
11,438 shares@ US$2.994.7% of flowCommon SharesSEC:0000912282-26-000411:0
5,650 shares@ US$1.697.7% of flowCommon SharesSEC:0000912282-25-001429:0
Canonical exit: 16 Mar 2026 (T+90)
28,000 shares@ US$1.7017.2% of flowCommon SharesSEC:0000912282-25-001427:0
Canonical exit: 16 Mar 2026 (T+90)
40,000 shares@ US$1.7669.7% of flowCommon SharesSEC:0000912282-25-001424:0
Canonical exit: 15 Mar 2026 (T+90)
32,000 shares@ US$1.5922.9% of flowCommon SharesSEC:0000912282-25-001423:0
Canonical exit: 15 Mar 2026 (T+90)
12,000 shares@ US$1.619965.3% of flowCommon SharesSEC:0000912282-25-001421:0
Canonical exit: 15 Mar 2026 (T+90)
21,000 shares0Common SharesSEC:0000912282-25-001290:0
21,000 shares0Common SharesSEC:0000912282-25-001288:0
21,000 shares0Common SharesSEC:0000912282-25-001286:0
21,000 shares0Common SharesSEC:0000912282-25-001283:0
123,000 shares0Common SharesSEC:0000912282-25-001299:0
32,000 shares0Common SharesSEC:0000912282-25-001298:0
317,000 shares0Common SharesSEC:0000912282-25-001294:0
107,000 shares0Common SharesSEC:0000912282-25-001292:0
21,000 shares0Common SharesSEC:0000912282-25-001281:0
21,000 shares0Common SharesSEC:0000912282-25-001279:0
25,000 shares0Common SharesSEC:0000912282-25-000934:0
2,500 shares@ US$4.37564.0% of flowCommon SharesSEC:0000912282-25-000718:0
Canonical exit: 23 Sept 2025 (T+90)
25 of 75 declarations
About Rezolute, Inc.
Rezolute, Inc. (ticker: RZLT) is a United States-based biopharmaceutical company listed on Nasdaq, with headquarters in Redwood City, California. For French-, Belgian- and Swiss-based investors, the company fits squarely into the specialty rare-disease segment: it is focused on a medically underserved condition characterized by recurrent, sometimes severe hypoglycemia driven by hyperinsulinism. Rezolute is not a diversified pharma group; it is a late-stage clinical developer whose equity story is largely tied to execution in a narrow therapeutic area.
The company traces its origins back to its former identity as AntriaBio, Inc., before adopting the Rezolute name in December 2017. Since then, management has sharpened the strategic focus around ersodetug, a fully human monoclonal antibody designed to bind allosterically to the insulin receptor and reduce receptor over-activation from insulin and related substances. In practical terms, the drug candidate is intended to address the dangerous glucose drops associated with hyperinsulinism, a condition that can be chronic, complex, and difficult to manage.
Read moreShow less
Rezolute’s current pipeline is centered on two Phase 3 programs: congenital hyperinsulinism and tumor hyperinsulinism. This concentrated pipeline gives the company a clear scientific and commercial narrative, but it also creates binary development risk. Competitive positioning is therefore defined less by broad scale and more by potential first- or best-in-class differentiation in a rare disease space where clinical efficacy, durability, safety, and regulatory alignment are crucial.
Recent news flow has been important for the investment case. In December 2025, the company disclosed topline results from the sunRIZE study. In March 2026, following a Type B meeting with the U.S. FDA, Rezolute said the agency encouraged submission of comprehensive data from sunRIZE and the ongoing open-label extension to help determine next steps. In May 2026, the company presented expanded analyses at the Pediatric Endocrine Society 2026 Annual Meeting, highlighting additional glucose-monitoring endpoints and ongoing patient exposure in the extension study.
Geographically, Rezolute remains primarily anchored in the United States, with clinical operations conducted through study sites used in its development programs. For investors tracking U.S. small- and mid-cap biotech on Nasdaq, the company is best viewed as a catalyst-driven rare-disease story with meaningful upside potential, but also with material clinical and regulatory risk.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
